Slingshot members are tracking this event:
Merck (MRK) Presents Phase 3 Results Evaluating Inactivated Varicella Zoster Vaccine (VZV) V212 for the Prevention of Herpes Zoster (HZ) (Shingles)
Slingshot Insights Explained
Feb 24, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3, Inactivated Varicella Zoster Virus Vaccine, V212, Herpes Zoster, Shingles